II. Indications

  1. See NSAID
  2. FDA approved indications
    1. Rheumatoid Arthritis
    2. Osteoarthritis
    3. Mild to moderate pain
    4. Primary Dysmenorrhea
  3. Off-Label (Non-FDA approved) Indications
    1. Juvenile Rheumatoid Arthritis

III. Contraindications

  1. See NSAID

IV. Mechanism

  1. See NSAID
  2. NSAID in the propionic acid class
    1. Other NSAIDS in propionic acid class include Ibuprofen and Naproxen

V. Medications

  1. Ketoprofen (Orudis) Immediate Release Capsules: 25 mg, 50 mg, 75 mg
  2. Ketoprofen (Orudis) Extended Release Capsules: 200 mg

VI. Dosing: Adult

  1. Immediate Release
    1. Arthritis (RA, OA): 75 mg orally three times daily (or 50 mg orally every 6 hours)
    2. Mild to moderate pain (including Dysmenorrhea): 25 to 50 mg orally every 6 to 8 hours
  2. Extended-Release
    1. Arthritis (RA, OA): 200 mg orally daily

VII. Dosing: Child

  1. Juvenile Rheumatoid Arthritis (not FDA approved)
    1. Start 100 to 200 mg/m2/day in divided doses 3 to 4 times daily
    2. Maximum: 320 mg/day

VIII. Adverse Effects

  1. See NSAID

IX. Safety

  1. See NSAID
  2. Avoid in Lactation
  3. Avoid NSAIDs in pregnancy outside the first part of the second trimester (13 to 20 weeks)
    1. Teratogenic in first trimester
    2. Risk of premature ductus arteriosus closure in the fetus in third trimester
    3. Most NSAIDs carry a legacy system Pregnancy Category B or C designation (aside from third trimester)
      1. However, many obstetricians avoid NSAIDs entirely in pregnancy (even in second trimester)

X. Efficacy

  1. Ketoprofen 25 mg comparable to Ibuprofen 400 mg
  2. Ketoprofen 50 mg more potent than Tylenol #3

XII. References

  1. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Ketoprofen (C0022635)

Definition (NCI) A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic effects. Ketoprofen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of ibuprofen. Ketoprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.
Definition (MSH) An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D007660
SnomedCT 363608003, 10099000, 386832008
LNC LP18985-9, MTHU007198
English 2-(3-Benzoylphenyl)propionic Acid, Benzoylhydratropic Acid, Benzeneacetic acid, 3-benzoyl-alpha-methyl-, ketoprofen, Benzeneacetic Acid, 3-benzoyl-alpha-methyl-, Capisten, Propionic Acid, 2-(3-benzoylphenyl)-, ketoprofen (medication), KETOPROFEN, Ketoprofen [Chemical/Ingredient], Ketoprofen, Ketoprofen product, Ketoprofen product (substance), Ketoprofen (product), Ketoprofen (substance)
Swedish Ketoprofen
Czech ketoprofen
Finnish Ketoprofeeni
Russian KETOPROFEN, BENZOILGIDROTROPNAIA KISLOTA, БЕНЗОИЛГИДРОТРОПНАЯ КИСЛОТА, КЕТОПРОФЕН
Japanese ベンゾイルヒドラトロパ酸, ケトプロフェン, 2-(3-ベンゾイルフェニル)プロパン酸
Italian Acido benzoil-idratropico, 2-(3-benzoilfenil)acido propionico, Ketoprofene
Croatian KETOPROFEN
Spanish Cetoprofeno, Ketoprofen, Cetoprofen, Ketoprofeno, Quetoprofeno, cetoprofeno, ketoprofeno (producto), ketoprofeno (sustancia), ketoprofeno, Ácido Benzoilhidratrópico
Polish Ketoprofen
Portuguese Ácido Benzoil-Hidratrópico, Ácido Benzoilidratrópico, Cetoprofeno
French Kétoprofène
German Ketoprofen, Benzoylhydratropsäure